GLP-1 · Semaglutide · Tirzepatide

GLP-1 Marketing Agency

We're not a GLP-1 media buyer — we're the creative team that builds the ads your media buyer tests. Semaglutide, tirzepatide, Ozempic-alternative, and compounded GLP-1 creative that clears compliance review and actually converts.

Get in Touch

We plug into your media buyer. We don't replace them.

The highest-converting GLP-1 ads are also the most legally dangerous.

GLP-1 is the most competitive paid-social category in telehealth right now. The FDA has issued multiple warning-letter waves targeting compounded GLP-1 advertisers making before/after claims or implying equivalence to Ozempic or Wegovy. Meta has a dedicated "weight loss" category flag that triggers review on content that used to run without issue. The creative that converts best — real transformations, specific outcomes, brand-name comparisons — is exactly the creative most likely to get your ad account flagged.

Most brands either over-correct (bland, generic, claim-free copy that doesn't convert) or under-correct (bold creative that converts until it gets them banned). The answer isn't to choose between performance and compliance. It's to work with a creative team who knows where the lines actually are.

We build GLP-1 creative that pushes hard on emotional resonance — the access narrative, the consultation experience, the "finally something that works" moment — without touching the claim categories that invite enforcement.

Creative built for the GLP-1 buyer.

Formats, angles, and creator profiles specific to the semaglutide/tirzepatide category. Your media buyer tests and optimizes — we produce the fuel.

Patient Journey Format

Real GLP-1 users telling their story without specific weight numbers. The hook is the experience: consultation, first injection, energy shift, sustained results. Avoids FTC substantiation traps while staying emotionally true.

Physician Authority Format

MD or PA on camera explaining how GLP-1 agonists work, who qualifies, and why telehealth access changes the equation. Builds category trust, not brand-specific claims.

Compounded vs. Brand-Name Creative

Distinct creative lanes for compounded semaglutide/tirzepatide that never imply equivalence to Ozempic, Wegovy, Zepbound, or Mounjaro. Angles: access, cost, availability, personalized dosing.

Access + Affordability Angle

Leads with the insurance gap and cash-pay option. No drug claims needed — the hook is "finally accessible without a 6-month waitlist."

Side-Effect Normalization Creative

Addresses nausea, titration, and expectation-setting. Reduces churn concern at the creative level before the patient even subscribes.

Skeptic-to-Believer Arc

Opens with resistance ("I thought this was another fad") and resolves with medically supervised conviction. Works well for audiences who've tried and failed with diet programs.

Creator Types

Real GLP-1 users with authentic documented journeys. Licensed physicians and PAs. Health-adjacent creators with credibility in the wellness space.

What the FDA and FTC actually regulate in GLP-1 advertising.

Before/After Imagery

FTC substantiation rules require that any before/after result be typical, not exceptional. We build testimonial creative around experience and access rather than specific outcome claims.

Brand-Name Comparisons

Ads that reference Ozempic, Wegovy, Mounjaro, or Zepbound in the context of a compounded product are a direct invitation for an FDA warning letter. We build compounded GLP-1 creative that stands on its own.

FDA Warning-Letter Waves

FDA has specifically targeted compounded GLP-1 advertisers making efficacy claims equivalent to approved drugs. Our scripts are reviewed against the specific language patterns FDA has flagged.

Meta Weight Loss Category

Meta flags and manually reviews ads in the "weight loss" interest category. We build creative that passes that review without losing conversion power.

"Lose X Pounds" Claims

Specific weight loss outcome claims require FTC substantiation. We use experiential framing instead.

Compounded Drug Disclaimers

Every compounded product ad includes appropriate Rx/consultation disclaimers and does not make FDA-approval equivalence claims.

$50M+

Creative managed across telehealth brands

100M+

Organic views generated from our creative

2,500+

Ads produced across GLP-1, TRT, ED, hair loss, peptides

How It Works

Four steps from brief to your media buyer's dashboard.

Strategy Call

We audit your current creative approach, map your buyer's angles, and identify the gaps your media buyer needs filled.

Creative Brief

We develop the angles, hooks, and creator profiles. You approve the strategy before a single frame is shot.

Production

We source the right creators, direct and produce the content, and review every script against FDA, FTC, and platform policies.

Delivered to Your Media Buyer

We hand over a complete batch of tested creative assets. Your media buyer runs the ads. They report back top performers. We iterate.

Frequently Asked Questions

Can you create ads for compounded semaglutide or tirzepatide?

Yes. We build creative specifically for compounded GLP-1 products. The key is constructing creative that never implies equivalence to Ozempic, Wegovy, Zepbound, or Mounjaro — instead, the creative leads with access, personalization, and the telehealth consultation model. See our compliance guide at /blog/telehealth-advertising-compliance/compounding-pharmacy-telehealth-ads for more detail.

What are the actual rules on before/after imagery for GLP-1 ads?

FTC substantiation rules require that any before/after result shown be representative of typical outcomes, and require a clear disclaimer when results aren't typical. Meta additionally restricts imagery that implies negative body assessment. We build creative that uses transformation framing without crossing either line — typically by focusing on how patients feel and what became possible, rather than specific measurements. More on this at /blog/telehealth-advertising-compliance/before-after-claims-telehealth.

Why do GLP-1 ads keep getting rejected on Meta?

Three main reasons: weight loss category flags trigger manual review, brand-name GLP-1 comparisons trigger trademark and drug policy issues, and before/after imagery violates Meta's body image policies. We've mapped the specific patterns that cause rejection and build creative around them. See /blog/telehealth-advertising-compliance/telehealth-ads-rejected-meta.

Do you run our ads for us?

No. We are a creative agency — we build the ads; your media buyer runs them. We intentionally don't operate ad accounts so there's no conflict of interest between creative output and media spend decisions. Your buyer tests, identifies top performers, and reports back. We use that signal to produce the next batch.

How is working with you different from a general creative or social media agency?

A general agency applies consumer packaged goods or D2C creative playbooks to a regulated Rx category and gets your account flagged. We work exclusively in telehealth. Our scripts are reviewed against FDA and FTC standards before delivery. Our creators have documented experience with GLP-1 products. And we know that what converts in weight loss creative is fundamentally different from what converts in CPG. Read more at /blog/glp1-marketing.

YOUR MEDIA BUYER NEEDS CREATIVE. WE BUILD IT.

Book a strategy call. We'll map out exactly what creative your media buyer needs to test next — and what a full production batch looks like for your vertical.

Get in Touch

Or email us at sales@telehealthmedia.com